BMY - Bristol-Myers Squibb Company
47.52 +0.22 (0.47%)
Pre-Market: 7:19AM EDT
| Previous Close | 47.74 |
| Open | 47.51 |
| Bid | 47.52 x 4000 |
| Ask | 47.83 x 900 |
| Day's Range | 46.89 - 47.64 |
| 52 Week Range | 44.30 - 63.69 |
| Volume | 9,540,097 |
| Avg. Volume | 18,197,006 |
| Market Cap | 77.37B |
| Beta (3Y Monthly) | 0.85 |
| PE Ratio (TTM) | 15.06 |
| EPS (TTM) | 3.14 |
| Earnings Date | Jul 24, 2019 - Jul 29, 2019 |
| Forward Dividend & Yield | 1.64 (3.53%) |
| Ex-Dividend Date | 2019-04-04 |
| 1y Target Est | 57.30 |
- Business Wire•1 hour ago
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
Bristol-Myers Squibb Company announced today the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the ...
- Zacks•16 hours ago
Synlogic (SYBX) Enters Cancer Collaboration with Roche
Synlogic (SYBX) announces clinical collaboration with Roche to develop its pre-clinical cancer candidate in combination with Roche's PD-L1 inhibitor, Tecentriq.
- Zacks•16 hours ago
Novartis Reports Data on Asthma Drug, Update from Annual Meet
Novartis (NVS) reports encouraging data on combination asthma drug. The company also highlights its growth plans at its annual meet.
- Zacks•2 days ago
Array BioPharma Gains on Colorectal Cancer Study Success
Array BioPharma's (ARRY) phase III study, evaluating the Braftovi triplet for treating metastatic colorectal cancer, meets the primary goal of ORR and OS. Shares rally.
- Zacks•2 days ago
Mallinckrodt (MNK) Down After Filing Suit Against HHS and CMS
Mallinckrodt (MNK) declines after filing suit against HHS and CMS for the protection of Medicaid patient access to Acthar.
- Benzinga•2 days ago
Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond
Two big pharma titans are battling for supremacy in the field of oncology immunotherapy. From the looks of it, Kenilworth, New Jersey-based Merck & Co., Inc. (NYSE: MRK) may have the upper hand over Bristol-Myers Squibb Co (NYSE: BMY). Before poring over the specifics, here's what immunotherapy means: it's a type of cancer treatment that uses the body's immune system to put up a fight against cancer cells.
- Zacks•2 days ago
Merck to Buy Private Cancer Drugmaker Peloton Therapeutics
Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.
- Barrons.com•2 days ago
Bristol-Myers Stock Continues to Slump, but Director Ted Samuels Is Buying Up Shares
Ted Samuels paid $236,440 for 5,000 shares last week. It’s the first open-market purchase of Bristol-Myers stock by an insider in a year.
- GuruFocus.com•4 days ago
4 New Stock Picks From Seth Klarman
While value investors continue to read through Seth Klarman (Trades, Portfolio)'s most recent partnership letter, others are tracking his latest filings to see what the guru has deemed worthy of buying. Warning! GuruFocus has detected 3 Warning Sign with CDAY.
- Benzinga•4 days ago
Argus Questions Logic Behind Bristol-Myers' Proposed Celgene Buy, Steps To Sidelines
Bristol-Myers Squibb's growth prospects following the planned acquisition of Celgene are a cause of concern, Toung said in a Friday downgrade note. Revlimid is Celgene's best-selling multiple myeloma drug and showed 15-percent year-over-year growth to $2.58 billion in the first quarter of 2019. It fetched roughly 64 percent of the company's revenues.
- MarketWatch•4 days ago
Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices
The spending by the industry’s main trade group and seven key drugmakers has climbed to a level not seen in a decade.
- Barrons.com•4 days ago
Bristol-Myers Stock Is Falling Because the Celgene Merger May Not Make Sense
A stormy honeymoon could be in the offing following the biggest pharmaceutical acquisition in history, according to one analyst.
- Zacks•7 days ago
Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL
Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
- Zacks•7 days ago
Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid
Celgene (CELG) obtains approval for the label expansion of oncology drugs Revlimid and Imnovid in Europe.
- Business Wire•8 days ago
Bristol-Myers Squibb to Present New Data on 20 Types of Cancer from Across its Oncology Portfolio at ASCO and EHA 2019
New data on Opdivo plus Yervoy in patients with advanced hepatocellular carcinoma and in melanoma patients with symptomatic brain metastases
- TheStreet.com•8 days ago
Bristol-Myers Squibb: A Long Idea for Aggressive Traders Only
In the Lightning Round of Wednesday's Mad Money program, Jim Cramer favored Bristol-Myers Squibb Co. which has been in a downtrend from August," Cramer told viewers. In the daily bar chart of BMY, below, we can identify three trends in the past twelve months.
- GlobeNewswire•8 days ago
Biocartis Group NV: Idylla(TM) MSI Performance Study Selected for Publication at ASCO Conference
PRESS RELEASE : 16 May 2019, 07:00 CEST Idylla(TM) MSI Performance Study Selected for Publication at ASCO Conference Mechelen, Belgium, 16 May 2019 - Biocartis Group NV (the `Company` or `Biocartis`), ...
- Zacks•9 days ago
Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
- CNBC•10 days ago
Lawsuit accuses Gilead of propping up cost of lifesaving HIV treatments by blocking generic competition
Pharmaceutical giant Gilead Sciences engaged in a "long-running scheme" to block generic competition of its combination drug "cocktails" to treat HIV. The complaint, filed in the U.S. District Court in San Francisco, names drugmakers Bristol-Myers Squibb and Johnson & Johnson subsidiary Janssen Pharmaceuticals as co-defendants. The plaintiffs in the suit claim that Gilead's actions caused the cost of the life-saving treatment to rise.
- GuruFocus.com•10 days ago
These Sleepy Stocks Have Done Nothing, But May Wake Up
This is a club for stocks that have hardly budged from where they were a month ago, and a year ago. Such stocks are often neglected by investors and sometimes by analysts too. Warning! GuruFocus has detected 3 Warning Signs with FLR.
- Zacks•10 days ago
Zacks.com featured highlights include: BlackRock, Northrop, Progressive, Interpublic Group and Bristol-Myers
Zacks.com featured highlights include: BlackRock, Northrop, Progressive, Interpublic Group and Bristol-Myers
- Business Wire•10 days ago
Award-Winning Actor and Producer Sterling K. Brown Joins Bristol-Myers Squibb in Effort to Share Stories of What It’s Like to Live with Cancer Today
Two-time Emmy Award winner Sterling K. Brown (This Is Us, Black Panther) is partnering with Bristol-Myers Squibb on a series designed to illuminate the triumphs and challenges of life after a cancer diagnosis. Survivorship Today: What It’s Like to Live with Cancer explores the stories of people who have experienced lasting physical, emotional and social effects from cancer to build greater understanding of, and draw attention to, survivorship-related issues. Today, more people who have been diagnosed with cancer are able to live with the disease than ever before.
- Business Wire•10 days ago
Bristol-Myers Squibb to Take Part in the UBS Global Healthcare Conference
Bristol-Myers Squibb Company will take part in a fireside chat at the UBS Global Healthcare Conference on Tuesday, May 21, 2019, in New York. Giovanni Caforio, M.D., chairman and chief executive officer will answer questions at 2:30 p.m.
- GuruFocus.com•11 days ago
Why Bristol-Myers Squibb's $19 Billion Debt Issuance to Buy Celgene Makes Sense
Bristol-Myers Squibb's (BMY) move to raise close to $20 billion in debt to acquire Celgene (CELG) looks dangerous, but years from now it may be considered a savvy move. True, the huge aggregate number of $58 billion in combined debt between the two companies certainly doesn't look all that flattering, especially in the context of threats by all three credit rating agencies - Moody's, Fitch and S&P Global Ratings - to downgrade the company's credit rating. The ratings agencies correctly cite total debt at 4x earnings, and that makes the corporate bond markets justifiably jittery.
- Zacks•11 days ago
Buy These 5 Stocks With Impressive Sales Growth Right Away
Sales growth is a key measure for any company, as it is important for growth projections and strategic decision making.
